Rigel Pharmaceuticals | 8-K: Current report
Rigel Pharmaceuticals | 8-K: Current report
Rigel Pharmaceuticals | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
Rigel Pharmaceuticals | 8-K: Press Release, dated August 6, 2024, titled “Rigel Reports Second Quarter 2024 Financial Results and Provides Business Update.”
Rigel Pharmaceuticals | S-3: Registration statement for specified transactions by certain issuers
Rigel Pharmaceuticals | 8-K: Current report
Rigel Pharmaceuticals | 8-K: Current report
Rigel Pharmaceuticals | 8-K: Current report
Rigel Pharmaceuticals | 8-K: Rigel Reports First Quarter 2024 Financial Results and Provides Business Update
Rigel Pharmaceuticals | 8-K: Current report
Rigel Pharmaceuticals | DEFA14A: Others
Rigel Pharmaceuticals | DEF 14A: Definitive information statements
Rigel Pharmaceuticals | PRE 14A: Preliminary proxy statements relating to merger or acquisition
Rigel Pharmaceuticals | 8-K: Rigel Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Rigel Pharmaceuticals | 8-K: Current report
Rigel Pharmaceuticals | 8-K: Current report
Rigel Pharmaceuticals | 8-K: Current report
Rigel Pharmaceuticals | 8-K: Rigel Reports Third Quarter 2023 Financial Results and Provides Business Update
Rigel Pharmaceuticals | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
Rigel Pharmaceuticals | 8-K: Rigel Reports Second Quarter 2023 Financial Results and Provides Business Update
No Data
No Data